David A. Siegel Forte Biosciences, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.82 $836 - $1,804	-2,200 Reduced 8.15%	24,791 $20,000
Q3 2023 Nov 14, 2023	SELL	$0.65 - $1.04 $19,890 - $31,824	-30,600 Reduced 53.13%	26,991 $17,000
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.11 $7,546 - $8,547	-7,700 Reduced 11.79%	57,591 $59,000
Q1 2023 May 15, 2023	SELL	$0.98 - $1.06 $5,488 - $5,936	-5,600 Reduced 7.9%	65,291 $65,000
Q4 2022 Feb 14, 2023	SELL	$0.96 - $28.0 $82,142 - $2.4 Million	-85,565 Reduced 54.69%	70,891 $70,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.75 $17,527 - $458,846	-16,535 Reduced 9.56%	156,456 $167,000
Q2 2022 Aug 15, 2022	SELL	$1.07 - $1.55 $66,768 - $96,720	-62,400 Reduced 26.51%	172,991 $225,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.24 $22,143 - $40,992	-18,300 Reduced 7.21%	235,391 $344,000
Q4 2021 Feb 14, 2022	BUY	$2.02 - $3.36 $512,455 - $852,401	253,691 New	253,691 $543,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$977,456
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $114M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.